These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 18383843)

  • 21. Gemcitabine and S-1 combination chemotherapy versus gemcitabine alone for locally advanced and metastatic pancreatic cancer: a meta-analysis of randomized controlled trials in Asia.
    Li Y; Sun J; Jiang Z; Zhang L; Liu G
    J Chemother; 2015 Aug; 27(4):227-34. PubMed ID: 25790948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.
    Saeki H; Yanoma S; Takemiya S; Sugimasa Y; Akaike M; Yukawa N; Rino Y; Imada T
    Oncol Rep; 2007 Aug; 18(2):433-9. PubMed ID: 17611667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. New treatment strategy with nuclear factor-κB inhibitor for pancreatic cancer.
    Horiuchi T; Uwagawa T; Shirai Y; Saito N; Iwase R; Haruki K; Shiba H; Ohashi T; Yanaga K
    J Surg Res; 2016 Nov; 206(1):1-8. PubMed ID: 27916347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imexon enhances gemcitabine cytotoxicity by inhibition of ribonucleotide reductase.
    Roman NO; Samulitis BK; Wisner L; Landowski TH; Dorr RT
    Cancer Chemother Pharmacol; 2011 Jan; 67(1):183-92. PubMed ID: 20339847
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Clinical benefit of full-dose gemcitabine for advanced pancreatic cancer refractory to S-1+gemcitabine].
    Hachisuka H; Takahashi M; Kushima A; Nakamoto T; Takahashi K; Iwamura Y; Wakata M; Nagano K; Nakajima T; Nunomura M; Araki K
    Gan To Kagaku Ryoho; 2013 May; 40(5):639-42. PubMed ID: 23863590
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Contribution of thymidylate synthase to gemcitabine therapy for advanced pancreatic cancer.
    Komori S; Osada S; Mori R; Matsui S; Sanada Y; Tomita H; Tokuyama Y; Takahashi T; Yamaguchi K; Yoshida K
    Pancreas; 2010 Nov; 39(8):1284-92. PubMed ID: 20944490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. S-Adenosylmethionine synergistically enhances the antitumor effect of gemcitabine against pancreatic cancer through JAK2/STAT3 pathway.
    Liu Y; Bi T; Liu L; Gao Q; Shen G; Qin L
    Naunyn Schmiedebergs Arch Pharmacol; 2019 May; 392(5):615-622. PubMed ID: 30683944
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gimeracil, a component of S-1, may enhance the antitumor activity of X-ray irradiation in human cancer xenograft models in vivo.
    Fukushima M; Sakamoto K; Sakata M; Nakagawa F; Saito H; Sakata Y
    Oncol Rep; 2010 Nov; 24(5):1307-13. PubMed ID: 20878125
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells.
    Koga H; Selvendiran K; Sivakumar R; Yoshida T; Torimura T; Ueno T; Sata M
    Int J Oncol; 2012 Mar; 40(3):679-85. PubMed ID: 22020928
    [TBL] [Abstract][Full Text] [Related]  

  • 30.
    Yang H; Tong Z; Shen L; Sun YU; Hoffman RM; Huang J
    Anticancer Res; 2020 Sep; 40(9):4969-4978. PubMed ID: 32878785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dual inhibition of the PI3K and MAPK pathways enhances nab-paclitaxel/gemcitabine chemotherapy response in preclinical models of pancreatic cancer.
    Awasthi N; Kronenberger D; Stefaniak A; Hassan MS; von Holzen U; Schwarz MA; Schwarz RE
    Cancer Lett; 2019 Sep; 459():41-49. PubMed ID: 31153980
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.
    D'Aronzo M; Vinciguerra M; Mazza T; Panebianco C; Saracino C; Pereira SP; Graziano P; Pazienza V
    Oncotarget; 2015 Jul; 6(21):18545-57. PubMed ID: 26176887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.
    Namba T; Kodama R; Moritomo S; Hoshino T; Mizushima T
    Cell Death Dis; 2015 Jun; 6(6):e1795. PubMed ID: 26111057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients.
    Morizane C; Okusaka T; Ueno H; Kondo S; Ikeda M; Furuse J; Shinichi O; Nakachi K; Mitsunaga S; Kojima Y; Suzuki E; Ueno M; Yamaguchi T
    Cancer Chemother Pharmacol; 2012 Apr; 69(4):957-64. PubMed ID: 22120961
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro and in vivo evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer.
    Komoto M; Nakata B; Nishii T; Kawajiri H; Shinto O; Amano R; Yamada N; Yashiro M; Hirakawa K
    Cancer Sci; 2010 Feb; 101(2):468-73. PubMed ID: 19925494
    [TBL] [Abstract][Full Text] [Related]  

  • 36. hENT1 reverses chemoresistance by regulating glycolysis in pancreatic cancer.
    Xi Y; Yuan P; Li T; Zhang M; Liu MF; Li B
    Cancer Lett; 2020 Jun; 479():112-122. PubMed ID: 32200037
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effects of tumor necrosis factor-related apoptosis-inducing ligand alone and in combination with fluoropyrimidine anticancer agent, S-1, on tumor growth of human oral squamous cell carcinoma xenografts in nude mice.
    Itashiki Y; Harada K; Ferdous T; Yoshida H
    Anticancer Res; 2007; 27(4B):2365-75. PubMed ID: 17695527
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combined Analyses of hENT1, TS, and DPD Predict Outcomes of Borderline-resectable Pancreatic Cancer.
    Yabushita Y; Mori R; Taniguchi K; Matsuyama R; Kumamoto T; Sakamaki K; Kubota K; Endo I
    Anticancer Res; 2017 May; 37(5):2465-2476. PubMed ID: 28476815
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanisms of metformin's anti‑tumor activity against gemcitabine‑resistant pancreatic adenocarcinoma.
    Suzuki K; Takeuchi O; Suzuki Y; Kitagawa Y
    Int J Oncol; 2019 Feb; 54(2):764-772. PubMed ID: 30570108
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [A case of Complete Response(CR)to combination therapy of S-1 and Gemcitabine(GEM)for unresectable pancreatic cancer].
    Miyagawa K; Yata Y; Yamaoka N; Sagara Y
    Gan To Kagaku Ryoho; 2010 Jun; 37(6):1145-7. PubMed ID: 20567125
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.